ABVV Abviva Inc

[mickymoose99]

Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics

Buzz up! 0 Print..Companies:ABVIVA INC.Related Quotes
Symbol Price Change
ABVV.PK 0.05 0.00


{"s" : "abvv.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Abviva, Inc. On Monday May 17, 2010, 4:15 pm EDT
SANTA BARBARA, Calif., May 17 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets:ABVV.pk - News), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

"We are very pleased with this positive development," said Barrett Evans, CEO of Abviva. "Not only will these patent grants allow us to penetrate the Japanese market with proprietary technology, they further validate, along with previous patent grants covering 16 European countries, Canada, Australia, and the United States, the global patentability of the Mammastatin technology."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.

[stockplaya321]

Abviva, Inc., a development stage biomedical company, focuses on the development and commercialization of breast cancer diagnostic and therapeutic products derived from a human biological secreted protein, Mammastatin. The company, through its subsidiary, develops breast cancer screening products, which include the Mammastatin Serum Assay, a breast cancer diagnostic risk assessment test. It also holds equity interest in Prion Developmental Laboratories, Inc., which develops tests to detect transmissible spongiform encephalopathies, such as mad cow disease in cattle and chronic wasting disease in deer and elk. The company, formerly known as Genesis Bioventures, Inc., was founded in 1994 and is headquartered in Los Angeles, California.

[GreenGiant]

Abviva, Inc. (OTC.PK: ABVV)
Abviva, Inc. was established to develop and commercialize diagnostic and therapeutic products from a novel breast cancer growth inhibitory protein. Research scientists at the prestigious University of Michigan Cancer Center discovered a secreted protein produced in normal breast epithelial cells that inhibits the growth of breast cancer.

This discovery was developed into a diagnostic blood test for breast cancer, the Mammastatin Serum Assay (MSA). The MSA will be used to screen women for early detection of breast cancer. In clinical studies Mammastatin was found to be normally present in blood serum of healthy women and absent in women with breast cancer. Abviva intends to offer the MSA to women and their doctors through its wholly owned clinical reference laboratory, Biomedical Diagnostics, LLC.

Mammastatin was also shown to be a possible treatment for breast cancer. Palliative Stage IV women with terminal breast cancer were treated with an early therapeutic preparation of Mammastatin under Compassionate Use. Most of these women presented positive responses. Over half demonstrated regression of bone metastatic tumors. Lives were extended for over two years while on the Mammastatin therapy.

Mammastatin is normally present in healthy women and therefore comes

[RAZOR11]

ABVV has news out after the close yesterday. This is one thats going to explode. The charts all show positive movement with everything heading north. This news is going to bring us some nice gains today and this week. Keep this on your radar list. Here is the latest news.

SANTA BARBARA, Calif., May 17 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets:ABVV.pk - News), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

"We are very pleased with this positive development," said Barrett Evans, CEO of Abviva. "Not only will these patent grants allow us to penetrate the Japanese market with proprietary technology, they further validate, along with previous patent grants covering 16 European countries, Canada, Australia, and the United States, the global patentability of the Mammastatin technology."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

[stockplaya321]

Abviva�s research interests are directed toward innovating and developing breast cancer diagnostic and breast cancer therapeutic products that can benefit individuals throughout the world. Abviva intends to conduct basic, translational and clinical research with biotechnology, pharmaceutical and leading university and government institutions world wide through internal and external collaborative research. We intend that research conducted on mammastatin will advance the knowledge and understanding of the biological mechanisms underlying the mammastatin phenomenon as well as advance the scientific, medical, diagnostic and therapeutic understanding of mammastatin and breast cancer

[stockplaya321]

ABVV-News Alert!
This company traded more shares than it has ever traded before!! Stock did really well and we are at 2.5 million in volume so far! Was up at one point, by 60%!!! 10-day on this one is 11,590!! company came with great news last night- also hearing rumors swirling of possible news coming after the close!!! Do your DD, but IMO this company has what it takes for us to make HUGE GAINS on it!

Company Info:

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification

[GreenGiant]

ABVV-News Alert!
This company traded more shares than it has ever traded before!! Stock did really well and we are at 2.5 million in volume so far! Was up at one point, by 60%!!! 10-day on this one is 11,590!! company came with great news last night- also hearing rumors swirling of possible news coming after the close!!! Do your DD, but IMO this company has what it takes for us to make HUGE GAINS on it!

Company Info:

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.

[RAZOR11]

Heres another pr from ABVV. This one exploded on the last news release. I think were are going to have another great run with some high volume and some nice gains again this week. Imo we are going to ahve a huge morning. Keep your eyes on this one!! Here is the news..

SANTA BARBARA, Calif., May 21 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets:ABVV.pk - News), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.

The Company previously announced that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

The international patents detail methods of use and compositions of Mammastatin in therapeutic and diagnostic applications in the United States (7 patents), Australia (2 patents), Canada (1), Europe (1), and Japan (2). These patents have issued starting in the United States and Australia in 2002, and continuing through the two most recent patents issued this year in Japan.

"Based upon the patents, we believe that we will be able to aggressively penetrate the largest markets worldwide with confidence that our intellectual property is secure," said Barrett Evans, CEO of Abviva. "There are additional patents that have been filed and we are hopeful that we will be able to obtain even further protection of our intellectual property as the Company grows."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells. In previous studies, an independent biostatistician calculated the overall accuracy of the MSA test to be 84-86%.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

[stocksalot]

The Company previously announced that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

The international patents detail methods of use and compositions of Mammastatin in therapeutic and diagnostic applications in the United States (7 patents), Australia (2 patents), Canada (1), Europe (1), and Japan (2). These patents have issued starting in the United States and Australia in 2002, and continuing through the two most recent patents issued this year in Japan.

"Based upon the patents, we believe that we will be able to aggressively penetrate the largest markets worldwide with confidence that our intellectual property is secure," said Barrett Evans, CEO of Abviva. "There are additional patents that have been filed and we are hopeful that we will be able to obtain even further protection of our intellectual property as the Company grows."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells. In previous studies, an independent biostatistician calculated the overall accuracy of the MSA test to be 84-86%.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."

[gucci88]

Abviva Inc. has some interesting movements along with spikes. looks like the investors and traders are very interested in their company mission and specialty. on watch with this one.

[stockplaya321]

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements

[RAZOR11]

Keep your eyes on ABVv this morning. This one isnt showing any life today but Imo this will have a late start. They stated in there last news statement that they have more patents in the works and there are rumors everywhere about news coming on this one.

Breast cancer is becoming very common in women and they have seen some cases starting to show in men. Reaserch shows that Mammastatin is deficient in women with breast cancer. Abviva has made a serum and is used on women with early breast detection and has amazing results. It has also been used on women with terminal breast cancer. The results from this have shown regression of bone metastatic tumorsand has extended there lives two years or more.

Imo this is a great company to take a position in. I belive they are on the right track in the battle with breast cancer. This company is definatly undervalued and in time will become a major player for the fight against breast cancer. The company is constanly looking for bigger and better ideas and there reasearch is what will make breast cancer a thing of the past!